-
1دورية أكاديمية
المؤلفون: Trifiletti D. M., Ballman K. V., Brown P. D., Anderson S. K., Carrero X. W., Cerhan J. H., Whitton A. C., Greenspoon J., Parney I. F., Laack N. N., Ashman J. B., Bahary J. -P., Hadjipanayis C. G., Urbanic J. J., Barker F. G., Farace E., Khuntia D., Giannini C., Buckner J. C., Galanis E., Roberge D.
المساهمون: Trifiletti D.M., Ballman K.V., Brown P.D., Anderson S.K., Carrero X.W., Cerhan J.H., Whitton A.C., Greenspoon J., Parney I.F., Laack N.N., Ashman J.B., Bahary J.-P., Hadjipanayis C.G., Urbanic J.J., Barker F.G., Farace E., Khuntia D., Giannini C., Buckner J.C., Galanis E., Roberge D.
مصطلحات موضوعية: Adult, Aged, 80 and over, Brain Neoplasm, Cognition Disorder, Confidence Interval, Cranial Irradiation, Dose Fractionation, Radiation, Female, Human, Kaplan-Meier Estimate, Lung Neoplasm, Male, Middle Aged, Proportional Hazards Model, Prospective Studie, Radiosurgery, Radiotherapy, Adjuvant, Quality Improvement
وصف الملف: STAMPA
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31654784; info:eu-repo/semantics/altIdentifier/wos/WOS:000506573200009; volume:106; issue:2; firstpage:255; lastpage:260; numberofpages:6; journal:INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; http://hdl.handle.net/11585/786019Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076574833
-
2دورية أكاديمية
المؤلفون: Galanis E., Keith Anderson S., Miller C. R., Sarkaria J. N., Jaeckle K., Buckner J. C., Ligon K. L., Ballman K. V., Moore D. F., Nebozhyn M., Loboda A., Schiff D., Ahluwalia M. S., Lee E. Q., Gerstner E. R., Lesser G. J., Prados M., Grossman S. A., Cerhan J., Giannini C., Wen P. Y.
المساهمون: Galanis E., Keith Anderson S., Miller C.R., Sarkaria J.N., Jaeckle K., Buckner J.C., Ligon K.L., Ballman K.V., Moore D.F., Nebozhyn M., Loboda A., Schiff D., Ahluwalia M.S., Lee E.Q., Gerstner E.R., Lesser G.J., Prados M., Grossman S.A., Cerhan J., Giannini C., Wen P.Y.
مصطلحات موضوعية: glioblastoma, histone deacetylase inhibitor, phase I/II trial, temozolomide, vorinostat, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, Brain Neoplasm, Cohort Studie, Female, Follow-Up Studie, Human, Male, Maximum Tolerated Dose, Middle Aged, Prognosi, Survival Rate, Young Adult, Chemoradiotherapy
وصف الملف: STAMPA
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29016887; info:eu-repo/semantics/altIdentifier/wos/WOS:000429448300013; volume:20; issue:4; firstpage:546; lastpage:556; numberofpages:11; journal:NEURO-ONCOLOGY; http://hdl.handle.net/11585/726691Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85045223336; http://neuro-oncology.oxfordjournals.org/current.dtlTest
الإتاحة: https://doi.org/10.1093/neuonc/nox161Test
http://hdl.handle.net/11585/726691Test
http://neuro-oncology.oxfordjournals.org/current.dtlTest
